Skip to main content

Table 2 Percentages of resistant phenotypes among Gram-positive and Gram-negative isolates by year, 2013—2016

From: The Tigecycline Evaluation and Surveillance Trial; assessment of the activity of tigecycline and other selected antibiotics against Gram-positive and Gram-negative pathogens from France collected between 2004 and 2016

 

E. coli ESBL-positive

K. pneumoniae ESBL-positive

H. influenzae BL positive

P. aeruginosa MDR

A. baumannii MDR

MRSA

 

n

%

n

%

n

%

n

%

n

%

n

%

2013

46

14.9

75

36.1

39

25.3

33

13.6

11

12.2

84

28.0

2014

43

15.6

85

40.7

27

18.9

21

9.8

10

13.5

76

27.9

2015

47

16.8

71

36.4

36

25.7

11

5.3

7

9.1

50

18.3

2016

20

19.8

34

43.6

20

35.1

3

4.0

7

24.1

24

23.5

  1. BL, β-lactamase, ESBL, extended-spectrum β-lactamase, MDR, multidrug-resistant, MRSA, methicillin-resistant S. aureus